Study on The Sensitizing Effect of Sonodynamic Therapy on The Treatment of Brainstem Glioma With Radiotherapy and Chemotherapy and Survival Analysis
Summary
1.Brief Introduction to the Research Background: You are invited to participate in a clinical study initiated by the First Affiliated Hospital of Zhengzhou University and chaired by Professor Zheng Yingjuan at our center. This two-year study aims to verify the sonodynamic therapy. It has been reviewed and approved for establishment by the Scientific Research Office of the First Affiliated Hospital of Zhengzhou University and has also obtained the approval of the Ethics Committee of the First Affiliated Hospital of Zhengzhou University to conduct the clinical research. This informed consent form provides you with relevant information about this clinical study to help you decide whether to participate. If you agree to participate, please read the following instructions carefully. If you have any questions, you can consult the researchers in charge of this study.
Timeline
- Start
- 2024-10-01
- Primary completion
- 2028-05-01
- Completion
- 2028-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hematoporphyrin | Small molecule | 5 mg/kg | — |
| Comparator | Temozolomide | Small molecule | 75 mg/m2 | — |
| Comparator | Temozolomide | Small molecule | 150 mg/m2 | — |
| Comparator | Temozolomide | Small molecule | 200 mg/m2 | — |
| Comparator | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Comparator | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |